Central Pharmaceuticals (DHA:CENTRALPHL) Research & Development: BDT0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:CENTRALPHL Central Pharmaceuticals Ltd DHA:CENTRALPHL
66 GF Score
Price BDT10.90
GF Value BDT12.04
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Central Pharmaceuticals Research & Development?

Central Pharmaceuticals DHA:CENTRALPHL +3.81% 66 Research & Development is BDT0.00 Mil as of Mar. 2026. GuruFocus rates DHA:CENTRALPHL with a GF Score™ of 66/100 and a GF Value™ of BDT12.04 (Fairly Valued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Central Pharmaceuticals's Research & Development for the three months ended in Mar. 2026 was BDT0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was BDT0.00 Mil.

Central Pharmaceuticals  (DHA:CENTRALPHL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Central Pharmaceuticals Research & Development Related Terms

Central Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Central Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Central Pharmaceuticals Research & Development Chart

Central Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Central Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
DHA:CENTRALPHL
66GF Score
Central Pharmaceuticals Ltd DHA:CENTRALPHL
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Central Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of BDT0.00 Mil mean?
Central Pharmaceuticals (DHA:CENTRALPHL) has a Research & Development of BDT0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Central Pharmaceuticals and its competitors.
Is Central Pharmaceuticals' Research & Development too high?
Central Pharmaceuticals' current Research & Development is BDT0.00 Mil. Overall, Central Pharmaceuticals has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Central Pharmaceuticals' Research & Development compare to ZTS and UTHR?
Central Pharmaceuticals' Research & Development of BDT0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Central Pharmaceuticals and its competitors. Central Pharmaceuticals's current Research & Development is BDT0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Central Pharmaceuticals (DHA:CENTRALPHL) is currently considered Fairly Valued. The stock's GF Value™ is BDT12.04, compared to a current price of BDT10.90 — trading 9.5% below its estimated fair value. The current Research & Development is BDT0.00 Mil. Central Pharmaceuticals' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Central Pharmaceuticals (DHA:CENTRALPHL), the current Research & Development is BDT0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Central Pharmaceuticals (DHA:CENTRALPHL) Overvalued in 2026?

Based on GuruFocus' analysis, Central Pharmaceuticals stock appears to be undervalued. The current stock price of BDT10.90 is trading 9.5% below its estimated GF Value™ of BDT12.04. GuruFocus considers Central Pharmaceuticals to be Fairly Valued.

Key valuation signals for DHA:CENTRALPHL:

  • Research & Development: BDT0.00 Mil
  • GF Value™: BDT12.04 vs. price of BDT10.90 (9.5% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the DHA:CENTRALPHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Central Pharmaceuticals Business Description

Address South West Darus Salam Road, 2-A/1, 2nd Floor, Mirpur - 1, Dhaka, BGD, 1216
Central Pharmaceuticals Ltd is engaged in the manufacturing and marketing of medicines in Bangladesh. The company manufactures finished pharmaceutical formulations, including tablets, capsules, liquids, ointments, and injectables, covering therapeutic areas such as anti-infectives, cardiovascular treatments, pain management, and gastrointestinal remedies. It conducts production and sales exclusively in the domestic market through its own facilities and distribution network. The company generates revenue from the sales of its pharmaceutical preparations.
66GF Score

Get the complete analysis for DHA:CENTRALPHL

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT10.90
Price
BDT12.04
GF Value